Ayotai

Aiotai is a clinical-stage biotechnology company focused on developing next-generation T cell receptor engineered T cell (TCR-T) therapies for solid tumors. Headquartered in Suzhou, China, the company utilizes a proprietary platform to discover and develop TCRs with high specificity and affinity for tumor-associated antigens. Its lead candidate, AIO-001, targets Hepatitis B virus (HBV) antigens for the treatment of HBV-related hepatocellular carcinoma, a major health challenge in Asia. Aiotai's pipeline also includes programs targeting neoantigens and shared tumor antigens like NY-ESO-1. The company is backed by prominent venture capital firms and aims to provide curative options for patients with advanced solid malignancies.